Communiqués Vivoryon Therapeutics N.V.

Actions

VVY

NL00150002Q7

Recherche biotechnologique et médicale

Temps réel Euronext Amsterdam 10:17:33 14/09/2026			Varia. 5j.	Varia. 1 janv.
1,085 ^EUR	-3,12%		-3,98%	-23,59%

07/08	Transcript : Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026
06/08	Vivoryon Therapeutics N.V. publie ses résultats pour le premier semestre clôturé au 30 juin 2026	CI

Communiqués

18/08	Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026	GL
06/08	Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update	GL
23/07	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026, Annual General Meeting Planned for End of September 2026	AQ
22/07	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026	GL
21/07	Vivoryon Therapeutics N : C. Christiansen - Vivoryon Therapeutics N.V. - Halle	PU
11/06	Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update	GL
08/06	Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026	GL
24/04	Vivoryon Therapeutics N : Jaarlijkse financiële verslaggeving	PU
23/04	Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update	GL
23/04	Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update	AQ
15/04	Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026	GL
09/04	Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference	GL
28/03	Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology	GL
09/03	Vivoryon Therapeutics N : Policy on bilateral contacts with shareholders	PU
09/03	Vivoryon Therapeutics N : Policy on bilateral contacts with stakeholders	PU
07/01	Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences	GL
04/12	Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates	GL
25/11	Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025	PU
25/11	Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025	GL
07/11	Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025	PU
06/11	Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025	GL
03/11	Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. to Present at Upcoming Conferences	PU
03/11	Vivoryon Therapeutics N.V. to Present at Upcoming Conferences	GL
09/10/25	Vivoryon Therapeutics N : Liechtensteinische Landesbank Aktiengesellschaft - Vivoryon Therapeutics N.V. - Halle	PU
07/10/25	Vivoryon Therapeutics N : Halle	PU